Silence Therapeutics plc' Partner, Quark Pharmaceuticals Inc., Extends its Agreement With Pfizer Inc. (PFE) to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication
5/3/2012 7:02:19 AM
More...
|
Quark Pharmaceuticals Inc. Announces Phase 2a Study of PF--04523655 (PF-655) in Patients With Moderate and Advanced Open-Angle Glaucoma (OAG)
5/1/2012 10:16:34 AM
More...
|
Quark Pharmaceuticals Inc. Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
1/4/2012 10:33:13 AM
More...
|
Regarding Announcement of Quark Pharmaceuticals Inc.
3/23/2011 10:18:42 AM
More...
|
Silence Therapeutics plc Partner Quark Pharmaceuticals Inc. Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema
3/21/2011 9:38:51 AM
More...
|
Quark Pharmaceuticals Inc.: In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
3/21/2011 8:44:44 AM
More...
|
Quark Pharmaceuticals Inc. Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
10/20/2010 10:24:41 AM
More...
|
Quark Pharmaceuticals Inc. Seeks Up to $20M IPO
9/27/2010 8:18:19 AM
More...
|
Quark Pharmaceuticals Inc. (QURK)'s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
6/28/2010 9:15:42 AM
More...
|
Quark Pharmaceuticals Inc. (QURK) Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010
6/24/2010 10:59:56 AM
More...
|
|